scholarly journals Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients not yet on Dialysis

2009 ◽  
Vol 4 (3) ◽  
pp. 560-566 ◽  
Author(s):  
Dana Rizk ◽  
Claudine Jurkovitz ◽  
Emir Veledar ◽  
Susan Bagby ◽  
Deborah A. Baumgarten ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Kidney Disease ◽  
Polycystic Kidney Disease ◽  
Autosomal Dominant ◽  
Polycystic Kidney ◽  
Autosomal Dominant Polycystic Kidney

Cardiovascular risk and quality of life in autosomal dominant polycystic kidney disease patients in therapy with tolvaptan: A pilot study

2020 ◽  
Vol 18 ◽  
Author(s):  
Silvia Lai ◽  
Marco Mangiulli ◽  
Adolfo M Perrotta ◽  
Antonietta Gigante ◽  
Ludovica Napoleoni ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Kidney Disease ◽  
Polycystic Kidney Disease ◽  
Autosomal Dominant ◽  
Clinical Laboratory ◽  
Intima Media Thickness ◽  
Polycystic Kidney ◽  
Autosomal Dominant Polycystic Kidney ◽  
The Impact

Introduction: ardiovascular (CV) complications are the most frequent cause of morbidity and mortality in autosomal dominant polycystic kidney disease (ADPKD) patients. In 2017, the Italian Medicines Agency authorised tolvaptan, a vasopressin V2 receptor antagonist, for the treatment of ADPKD, based on the Tolvaptan Phase 3 Efficacy and Safety Study in ADPKD (TEMPO 3: 4), TEMPO 4: 4 and Replicating Evidence of Preserved Renal Function: An Investigation of Tolvaptan Safety and Efficacy (REPRISE) studies. Aim of the study: To assess the impact of tolvaptan on CV risk and quality of life, evaluated by nutritional, inflammatory, metabolic, instrumental parameters and psychocognitive tests in ADPKD patients. Methods and Materials: We evaluated 36 patients with ADPKD; 10 patients (7 males, mean age 42.5±7.0 years) treated with tolvaptan and 26 controls (11 males, mean age 36.7±9.1 years). They underwent, at T0, monthly, and at T1 (1 year) clinical, laboratory and instrumental evaluation, in addition to psychocognitive tests. Results: In ADPKD patients treated with tolvaptan we found at T1 a decrease in carotid intima media thickness (p=0.048), epicardial adipose tissue thickness (p=0.002), C-reactive protein (p=0.026), sympathovagal balance during the night (p=0.045) and increases flow mediated dilation (p=0.023) with a reduction in depression (Hamilton and Beck tests, p=0.008 and p=0.002, respectively) compared with controls. Conclusions: These preliminary results suggest that treatment with tolvaptan could improve early atherosclerosis and endothelial dysfunction markers and improve the mood in ADPKD patients (probably by the acting on endothelial cell and adipocyte V2 receptors).

scholarly journals Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan

2020 ◽  
Vol 2 (2) ◽  
pp. 162-171
Author(s):  
Manuel A. Anderegg ◽  
Nasser A. Dhayat ◽  
Grit Sommer ◽  
Mariam Semmo ◽  
Uyen Huynh-Do ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Kidney Disease ◽  
Polycystic Kidney Disease ◽  
Autosomal Dominant ◽  
Polycystic Kidney ◽  
Autosomal Dominant Polycystic Kidney

scholarly journals The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kiyotaka Uchiyama ◽  
Chigusa Kitayama ◽  
Akane Yanai ◽  
Yoshitaka Ishibashi
Keyword(s):  
Quality Of Life ◽  
Renal Function ◽  
Kidney Disease ◽  
Polycystic Kidney Disease ◽  
Autosomal Dominant ◽  
Short Form ◽  
Urinary Biomarkers ◽  
Polycystic Kidney ◽  
Autosomal Dominant Polycystic Kidney

AbstractThe vasopressin V2 receptor antagonist tolvaptan delays the progression of autosomal dominant polycystic kidney disease (ADPKD). However, some patients discontinue tolvaptan because of severe adverse aquaretic events. This open-label, randomized, controlled, counterbalanced, crossover trial investigated the effects of trichlormethiazide, a thiazide diuretic, in patients with ADPKD receiving tolvaptan (n = 10) who randomly received antihypertensive therapy with or without trichlormethiazide for 12 weeks. The primary and secondary outcomes included amount and osmolarity of 24-h urine and health-related quality-of-life (HRQOL) parameters assessed by the Kidney Disease Quality of Life-Short Form questionnaire, renal function slope, and plasma/urinary biomarkers associated with disease progression. There was a significant reduction in urine volume (3348 ± 584 vs. 4255 ± 739 mL; P < 0.001) and a significant increase in urinary osmolarity (182.5 ± 38.1 vs. 141.5 ± 38.1 mOsm; P = 0.001) in patients treated with trichlormethiazide. Moreover, trichlormethiazide improved the following HRQOL subscales: effects of kidney disease, sleep, emotional role functioning, social functioning, and role/social component summary. No significant differences were noted in renal function slope or plasma/urinary biomarkers between patients treated with and without trichlormethiazide. In patients with ADPKD treated with tolvaptan, trichlormethiazide may improve tolvaptan tolerability and HRQOL parameters.

Sign in / Sign up

Export Citation Format

Share Document